Company profile

Biocodex

Privately held: no public share price (French family-owned pharmaceutical company (founded 1953 around the probiotic Saccharomyces boulardii), >€500M net revenue in 2023, operating in 100+ countries via 17 subsidiaries. Explicitly described as family-owned/private; no public listing found. Sources: https://clinicaltrials.gov/study/NCT05419180 ; https://api.gleif.org/api/v1/lei-records/969500JRK0RE7CYZSO20 ; https://api.gleif.org/api/v1/lei-records/894500BESE5JDYCZN529 ; https://www.biocodex.com/en/about-us/ Entity resolved by asset-pipeline-v2.)

Assets

(1 total)

1Total Assets

1Approved

0Phase 3 / Filed

0Phase 1–2 / Early

1Diseases

Showing 1 of 1 assets

		Target & Modality
Stiripentol	Approved	GABA-A receptorSmall molecule	Epilepsy

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.